FADS2 confers SCD1 inhibition resistance to cancer cells by modulating the ER stress response

Area of Science:

• Biochemistry
• Molecular Biology
• Cancer Research

Background:

• Stearoyl-CoA desaturase 1 (SCD1) is a key enzyme in fatty acid metabolism and a target for cancer therapy.
• Monotherapy with SCD1 inhibitors has shown limited clinical efficacy due to resistance mechanisms.
• Understanding resistance to SCD1 inhibition is crucial for developing effective combination therapies.

Purpose of the Study:

• To investigate the molecular mechanisms of cancer cell resistance to endoplasmic reticulum (ER) stress-induced cell death caused by SCD1 inhibition.
• To identify key factors determining sensitivity or resistance to SCD1 inhibitors.
• To explore novel therapeutic strategies involving combination therapy.

Main Methods:

• In vitro treatment of SCD1 inhibitor-sensitive and -resistant cancer cells with SCD1 inhibitors.
• Analysis of palmitic acid accumulation and ER stress response.
• Genetic depletion of fatty acid desaturase 2 (FADS2) using siRNA.
• Dual inhibition of SCD1 and FADS2 in resistant cancer cell lines.

Main Results:

• SCD1 inhibitor-sensitive cells accumulated palmitic acid and underwent ER stress-induced cell death.
• SCD1 inhibitor-resistant cells resisted cell death due to FADS2-mediated elimination of palmitic acid.
• FADS2 was identified as a critical determinant of cancer cell sensitivity/resistance to SCD1 inhibitors.
• Dual inhibition of SCD1 and FADS2 in A549 cells induced ER stress-dependent cancer cell death.

Conclusions:

• FADS2 plays a significant role in mediating resistance to SCD1 inhibitors in cancer cells.
• Combination therapy targeting both SCD1 and FADS2 presents a potential new strategy for cancer treatment.
• Targeting fatty acid metabolism through combined SCD1 and FADS2 inhibition offers a promising therapeutic avenue.